PDB Short entry for 1TKX HEADER TRANSFERASE 09-JUN-04 1TKX TITLE CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TITLE 2 GW490745 COMPND MOL_ID: 1; COMPND 2 MOLECULE: POL POLYPROTEIN, REVERSE TRANSCRIPTASE, CHAIN A; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 EC: 2.7.7.49; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: POL POLYPROTEIN, REVERSE TRANSCRIPTASE, CHAIN B; COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: P51; COMPND 11 EC: 2.7.7.49; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 STRAIN: HXB2 ISOLATE; SOURCE 5 GENE: POL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 10 ORGANISM_TAXID: 11676; SOURCE 11 STRAIN: HXB2 ISOLATE; SOURCE 12 GENE: POL; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HIV-1 REVERSE TRANSCRIPTASE, AIDS, NNRTI, GW490745, DRUG DESIGN, KEYWDS 2 TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR J.REN,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REVDAT 5 21-DEC-22 1TKX 1 REMARK SEQADV LINK REVDAT 4 31-JAN-18 1TKX 1 JRNL REVDAT 3 24-FEB-09 1TKX 1 VERSN REVDAT 2 28-DEC-04 1TKX 1 REMARK REVDAT 1 07-DEC-04 1TKX 0 JRNL AUTH G.A.FREEMAN,C.W.ANDREWS III,A.L.HOPKINS,G.S.LOWELL, JRNL AUTH 2 L.T.SCHALLER,J.R.COWAN,S.S.GONZALES,G.W.KOSZALKA,R.J.HAZEN, JRNL AUTH 3 L.R.BOONE,R.G.FERRIS,K.L.CREECH,G.B.ROBERTS,S.A.SHORT, JRNL AUTH 4 K.WEAVER,D.J.REYNOLDS,J.MILTON,J.REN,D.I.STUART, JRNL AUTH 5 D.K.STAMMERS,J.H.CHAN JRNL TITL DESIGN OF NON-NUCLEOSIDE INHIBITORS OF HIV-1 REVERSE JRNL TITL 2 TRANSCRIPTASE WITH IMPROVED DRUG RESISTANCE PROPERTIES. 2. JRNL REF J.MED.CHEM. V. 47 5923 2004 JRNL REFN ISSN 0022-2623 JRNL PMID 15537347 JRNL DOI 10.1021/JM040072R REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.REN,C.E.NICHOLS,P.P.CHAMBERLAIN,K.L.WEAVER,S.A.SHORT, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASES AT CODONS REMARK 1 TITL 2 100, 106 AND 108 AND MECHANISMS OF RESIST NON-NUCLEOSIDE REMARK 1 TITL 3 INHIBITORS REMARK 1 REF J.MOL.BIOL. V. 336 569 2004 REMARK 1 REFN ISSN 0022-2836 REMARK 1 REFERENCE 2 REMARK 1 AUTH P.P.CHAMBERLAIN,J.REN,C.E.NICHOLS,L.DOUGLAS,J.LENNERSTRAND, REMARK 1 AUTH 2 B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF ZIDOVUDINE- OR LAMIVUDINE-RESISTANT REMARK 1 TITL 2 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASES REMARK 1 TITL 3 CONTAINING MUTATIONS AT CODONS 41, 184, AND 215 REMARK 1 REF J.VIROL. V. 76 10015 2002 REMARK 1 REFN ISSN 0022-538X REMARK 1 REFERENCE 3 REMARK 1 AUTH J.REN,C.NICHOLS,L.BIRD,P.CHAMBERLAIN,K.L.WEAVER,S.A.SHORT, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL STRUCTURAL MECHANISMS OF DRUG RESISTANCE FOR MUTATIONS AT REMARK 1 TITL 2 CODONS 181 AND 188 IN HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 IMPROVED RESILIENCE OF SECOND GENERATION NON-NUCLEOSIDE REMARK 1 TITL 4 INHIBITORS REMARK 1 REF J.MOL.BIOL. V. 312 795 2001 REMARK 1 REFN ISSN 0022-2836 REMARK 1 REFERENCE 4 REMARK 1 AUTH J.H.CHAN,J.S.HONG,R.N.HUNTER III,G.F.ORR,J.R.COWAN, REMARK 1 AUTH 2 D.B.SHERMAN,S.M.SPARKS,B.E.REITTER,C.W.HAZEN, REMARK 1 AUTH 3 R.J.ANDREWS III,M.ST CLAIR,L.R.BOONE,R.G.FERRIS,K.L.ROBERTS, REMARK 1 AUTH 4 G.B.CREE,S.A.SHORT,K.WEAVER,R.J.OTT,J.REN,A.HOPKINS, REMARK 1 AUTH 5 D.I.STUART,D.K.STAMMERS REMARK 1 TITL 2-AMINO-6-ARYLSULFONYLBENZONITRILES AS NON-NUCLEOSI REMARK 1 TITL 2 TRANSCRIPTASE INHIBITORS OF HIV-1 REMARK 1 REF J.MED.CHEM. V. 44 1866 2001 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 5 REMARK 1 AUTH J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS REMARK 1 TITL STRUCTURAL BASIS FOR THE RESILIENCE OF EFAVIRENZ (DMP-266) REMARK 1 TITL 2 TO DRUG RESISTANT MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE REMARK 1 REF STRUCTURE V. 8 1089 2000 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 6 REMARK 1 AUTH J.REN,C.NICHOLS,L.E.BIRD,T.FUJIWARA,H.SUGINOTO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL BINDING OF THE SECOND GENERATTION NON-NUCLEOSIDE INHIBITOR REMARK 1 TITL 2 S-1153 TO HIV-1 REVERSE TRANSCRIPTASE INVOLVES EXTENSIVE REMARK 1 TITL 3 MAIN CHAIN HYDROGEN BONDING REMARK 1 REF J.BIOL.CHEM. V. 275 14316 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 REFERENCE 7 REMARK 1 AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU, REMARK 1 AUTH 2 M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS REMARK 1 TITL PHENETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE INHIBITORS REMARK 1 TITL 2 OF HIV-1 AND HIV-2 REVERSE TRANSCRIPTASES: STRUCTURAL AND REMARK 1 TITL 3 BIOCHEMICAL ANALYSES REMARK 1 REF J.BIOL.CHEM. V. 275 5633 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 REFERENCE 8 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 NON-NUCLEOSIDE THIAZOLOISOINDOLINONE INHIBITORS TO HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE AND COMPARISON WITH MODELING STUDIES REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 9 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH IMPROVED REMARK 1 TITL 2 ACTIVITY AGAINST DRUG-RESISTANT HIV MUTANTS REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 10 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF REVERSE TRANSCRIPTASE IN COMPLEX WITH REMARK 1 TITL 2 CARBOXANILIDE DERIVATIVES REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 11 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 C.K.ROSS,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE MUTATIONS IN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CAN INDUCE LONG RANGE REMARK 1 TITL 3 CONFORMATIONAL CHANGES REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 REFERENCE 12 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.GARMAN,D.O.SOMERS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT CELL OF REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON DEHYDRATION REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 REFERENCE 13 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX BETWEEN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN RESISTANCE REMARK 1 TITL 4 MUTATIONS FOR THIS NON-NUCLEOSIDE INHIBITOR REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 REFERENCE 14 REMARK 1 AUTH A.L HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES,C.K.ROSS, REMARK 1 AUTH 2 T.MIYASAKA,R.T.WALKER,H.TANAKA,D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH INHIBITORS OF REMARK 1 TITL 2 THE HEPT SERIES REVEAL CONFORMATIONAL CHANGES RELEVANT TO REMARK 1 TITL 3 THE DESIGN OF POTENT NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 15 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH REMARK 1 TITL 2 9-CHLORO-TIBO: LESSONS FOR INHIBITOR DESIGN REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 16 REMARK 1 AUTH J.REN,R.M.ESNOUF,E.GARMAN,D.O.SOMERS,C.K.ROSS,I.KIRBY, REMARK 1 AUTH 2 J.KEELING,G.DARBY,E.Y.JONES,D.I.STUART,D.K.STAMMERS REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 17 REMARK 1 AUTH R.M.ESNOUF,J.REN,C.K.ROSS,E.Y.JONES,D.K.STAMMERS,D.I.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY REMARK 1 TITL 2 NON-NUCLEOSIDE INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 18 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY,J.E.WILSON, REMARK 1 AUTH 2 M.NORMAN,J.REN,R.M.ESNOUF,E.GARMAN,E.Y.JONES,D.I.STUART REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE DIFFRACTING TO 2.2 REMARK 1 TITL 2 ANGSTROM RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 2 REMARK 2 RESOLUTION. 2.85 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.85 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.63 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 2435079.360 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.3 REMARK 3 NUMBER OF REFLECTIONS : 26084 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.216 REMARK 3 FREE R VALUE : 0.287 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1260 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.008 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.85 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.95 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 90.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2243 REMARK 3 BIN R VALUE (WORKING SET) : 0.3440 REMARK 3 BIN FREE R VALUE : 0.3850 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 120 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.035 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7724 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 21 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 73.70 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 68.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.24000 REMARK 3 B22 (A**2) : -14.60000 REMARK 3 B33 (A**2) : 17.84000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.37 REMARK 3 ESD FROM SIGMAA (A) : 0.62 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.49 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.76 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 23.40 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.000 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 3.760 ; 3.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 6.340 ; 6.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 5.460 ; 4.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 8.760 ; 8.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.31 REMARK 3 BSOL : 37.56 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER_REP.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 DUE TO THE LOW RATIO BETWEEN THE NUMBER OF REFLECTIONS AND THE R REMARK 3 APPLIED TO ALL ATOMS DISTANT FROM REMARK 3 THE NNRTI-BINDING SITE(DEFINED AS ATOMS MORE THAN 25 ANGSTROM FROM REMARK 3 THE CA ATOM OF TYR188) THROUGHOUT REMARK 3 THE REFINEMENT. REMARK 4 REMARK 4 1TKX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 21-JUN-04. REMARK 100 THE DEPOSITION ID IS D_1000022734. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 04-JUN-98 REMARK 200 TEMPERATURE (KELVIN) : 289 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PHOTON FACTORY REMARK 200 BEAMLINE : BL-6A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : FUJI REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 26084 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.850 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : 4.050 REMARK 200 R MERGE (I) : 0.15400 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 5.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.85 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.9 REMARK 200 DATA REDUNDANCY IN SHELL : 2.76 REMARK 200 R MERGE FOR SHELL (I) : 0.52900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 0.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.29 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.38 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 69.10000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 36.40000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 54.85000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 36.40000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 69.10000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 54.85000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5630 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 46440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -26.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO A 1 REMARK 465 ILE A 2 REMARK 465 ASP A 67 REMARK 465 SER A 68 REMARK 465 LYS A 540 REMARK 465 GLY A 541 REMARK 465 ILE A 542 REMARK 465 GLY A 543 REMARK 465 GLY A 544 REMARK 465 ASN A 545 REMARK 465 GLU A 546 REMARK 465 GLN A 547 REMARK 465 VAL A 548 REMARK 465 ASP A 549 REMARK 465 LYS A 550 REMARK 465 LEU A 551 REMARK 465 VAL A 552 REMARK 465 SER A 553 REMARK 465 ALA A 554 REMARK 465 GLY A 555 REMARK 465 ILE A 556 REMARK 465 ARG A 557 REMARK 465 LYS A 558 REMARK 465 VAL A 559 REMARK 465 LEU A 560 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 SER B 3 REMARK 465 PRO B 4 REMARK 465 ILE B 5 REMARK 465 LYS B 65 REMARK 465 LYS B 66 REMARK 465 GLU B 89 REMARK 465 VAL B 90 REMARK 465 GLN B 91 REMARK 465 LEU B 92 REMARK 465 GLY B 213 REMARK 465 LEU B 214 REMARK 465 THR B 215 REMARK 465 THR B 216 REMARK 465 PRO B 217 REMARK 465 ASP B 218 REMARK 465 LYS B 219 REMARK 465 LYS B 220 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 PRO B 225 REMARK 465 PRO B 226 REMARK 465 PHE B 227 REMARK 465 LEU B 228 REMARK 465 TRP B 229 REMARK 465 MET B 230 REMARK 465 GLY B 231 REMARK 465 TYR B 232 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 4 44.47 -105.62 REMARK 500 LYS A 13 162.47 -46.16 REMARK 500 PRO A 14 107.12 -30.32 REMARK 500 LYS A 20 52.41 -141.90 REMARK 500 PRO A 52 1.05 -52.24 REMARK 500 ARG A 72 -167.70 -110.49 REMARK 500 LYS A 82 -0.69 -56.68 REMARK 500 GLN A 85 174.29 -53.59 REMARK 500 GLU A 89 146.17 -22.25 REMARK 500 GLN A 91 97.02 -21.22 REMARK 500 PRO A 97 -52.25 -22.98 REMARK 500 ASP A 110 76.81 -100.64 REMARK 500 VAL A 111 106.81 -44.40 REMARK 500 ASP A 113 60.68 -67.11 REMARK 500 ALA A 114 -76.75 -41.85 REMARK 500 TYR A 115 -71.46 -36.31 REMARK 500 PHE A 116 -0.02 -56.59 REMARK 500 ARG A 125 -49.33 -28.48 REMARK 500 ILE A 135 103.54 -58.06 REMARK 500 ASN A 136 76.65 47.66 REMARK 500 ASN A 137 57.36 37.25 REMARK 500 GLU A 138 -132.47 -83.07 REMARK 500 SER A 156 -74.79 -52.93 REMARK 500 PRO A 170 -71.15 -64.76 REMARK 500 ASP A 177 18.20 -67.15 REMARK 500 TYR A 183 118.81 -162.58 REMARK 500 MET A 184 -121.27 60.19 REMARK 500 ILE A 195 -44.18 -27.67 REMARK 500 ARG A 211 -6.52 -57.13 REMARK 500 THR A 216 111.70 11.09 REMARK 500 LYS A 219 -56.10 95.13 REMARK 500 LYS A 220 -74.38 -90.71 REMARK 500 GLN A 222 117.51 -35.12 REMARK 500 PRO A 225 156.12 -42.00 REMARK 500 PRO A 226 -174.56 -69.24 REMARK 500 MET A 230 72.43 31.92 REMARK 500 GLN A 242 108.88 -44.27 REMARK 500 VAL A 276 15.71 -142.23 REMARK 500 LYS A 311 30.49 -98.13 REMARK 500 PRO A 345 139.99 -35.55 REMARK 500 PHE A 346 -5.64 60.34 REMARK 500 ARG A 356 95.12 -55.59 REMARK 500 ARG A 358 79.66 -68.64 REMARK 500 HIS A 361 106.62 170.83 REMARK 500 TRP A 401 -75.42 -59.81 REMARK 500 THR A 403 -8.53 -59.78 REMARK 500 PRO A 412 -178.60 -54.48 REMARK 500 PRO A 420 153.46 -47.69 REMARK 500 GLN A 512 135.00 -178.88 REMARK 500 PRO B 14 123.72 -33.01 REMARK 500 REMARK 500 THIS ENTRY HAS 67 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GWB A 999 DBREF 1TKX A 1 560 UNP P04585 POL_HV1H2 156 715 DBREF 1TKX B 1 440 UNP P04585 POL_HV1H2 156 595 SEQADV 1TKX CSD A 280 UNP P04585 CYS 435 MODIFIED RESIDUE SEQRES 1 A 560 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 560 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 560 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 560 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 560 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 560 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 560 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 560 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 560 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 560 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 560 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 560 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 560 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 560 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 560 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 560 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 560 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 560 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 560 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 560 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 560 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 560 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 560 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 560 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 560 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 560 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 560 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 560 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 560 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 560 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 560 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 560 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 560 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 560 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 560 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 560 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 560 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 560 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 560 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 560 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 560 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 560 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY GLY ASN GLU SEQRES 43 A 560 GLN VAL ASP LYS LEU VAL SER ALA GLY ILE ARG LYS VAL SEQRES 44 A 560 LEU SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 440 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE MODRES 1TKX CSD A 280 CYS 3-SULFINOALANINE HET CSD A 280 8 HET GWB A 999 21 HETNAM CSD 3-SULFINOALANINE HETNAM GWB 4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3- HETNAM 2 GWB ISOPROPYLQUINOLIN-2(1H)-ONE HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 GWB C17 H16 F N O2 HELIX 1 1 THR A 27 GLU A 44 1 18 HELIX 2 2 PHE A 77 THR A 84 1 8 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 ALA A 114 VAL A 118 5 5 HELIX 5 5 ASP A 121 LYS A 126 1 6 HELIX 6 6 TYR A 127 ALA A 129 5 3 HELIX 7 7 GLY A 155 ASN A 175 1 21 HELIX 8 8 GLU A 194 ARG A 211 1 18 HELIX 9 9 THR A 253 TYR A 271 1 19 HELIX 10 10 VAL A 276 LEU A 282 1 7 HELIX 11 11 THR A 296 LEU A 310 1 15 HELIX 12 12 ASN A 363 GLY A 384 1 22 HELIX 13 13 GLN A 394 THR A 403 1 10 HELIX 14 14 THR A 473 SER A 489 1 17 HELIX 15 15 SER A 499 GLN A 509 1 11 HELIX 16 16 SER A 515 LYS A 528 1 14 HELIX 17 17 THR B 27 GLU B 44 1 18 HELIX 18 18 PHE B 77 THR B 84 1 8 HELIX 19 19 PRO B 97 LYS B 103 5 7 HELIX 20 20 GLY B 112 VAL B 118 5 7 HELIX 21 21 PHE B 124 ALA B 129 5 6 HELIX 22 22 SER B 134 GLU B 138 5 5 HELIX 23 23 LYS B 154 PHE B 160 1 7 HELIX 24 24 PHE B 160 ASN B 175 1 16 HELIX 25 25 GLU B 194 ARG B 211 1 18 HELIX 26 26 HIS B 235 TRP B 239 5 5 HELIX 27 27 VAL B 254 SER B 268 1 15 HELIX 28 28 VAL B 276 LEU B 283 1 8 HELIX 29 29 THR B 296 LEU B 310 1 15 HELIX 30 30 ASN B 363 GLY B 384 1 22 HELIX 31 31 GLN B 394 TRP B 402 1 9 HELIX 32 32 THR B 403 TRP B 406 5 4 HELIX 33 33 PRO B 420 GLN B 428 1 9 SHEET 1 A 2 VAL A 60 PHE A 61 0 SHEET 2 A 2 LEU A 74 VAL A 75 -1 O LEU A 74 N PHE A 61 SHEET 1 B 3 SER A 105 ASP A 110 0 SHEET 2 B 3 ASP A 186 SER A 191 -1 O VAL A 189 N THR A 107 SHEET 3 B 3 ILE A 178 TYR A 183 -1 N TYR A 181 O TYR A 188 SHEET 1 C 2 PHE A 130 ILE A 132 0 SHEET 2 C 2 ILE A 142 TYR A 144 -1 O ILE A 142 N ILE A 132 SHEET 1 D 4 PHE A 227 TRP A 229 0 SHEET 2 D 4 TYR A 232 LEU A 234 -1 O TYR A 232 N TRP A 229 SHEET 3 D 4 TRP A 239 VAL A 241 -1 O THR A 240 N GLU A 233 SHEET 4 D 4 HIS A 315 GLY A 316 -1 O GLY A 316 N TRP A 239 SHEET 1 E 5 LYS A 347 TYR A 354 0 SHEET 2 E 5 TRP A 337 GLU A 344 -1 N TYR A 339 O GLY A 352 SHEET 3 E 5 ILE A 326 LYS A 331 -1 N GLN A 330 O THR A 338 SHEET 4 E 5 LYS A 388 LEU A 391 1 O LYS A 390 N ALA A 327 SHEET 5 E 5 TRP A 414 PHE A 416 1 O GLU A 415 N PHE A 389 SHEET 1 F 2 HIS A 361 THR A 362 0 SHEET 2 F 2 GLN A 512 SER A 513 -1 O GLN A 512 N THR A 362 SHEET 1 G 5 GLN A 464 THR A 470 0 SHEET 2 G 5 LEU A 452 THR A 459 -1 N GLY A 453 O LEU A 469 SHEET 3 G 5 GLU A 438 ASN A 447 -1 N ASN A 447 O LEU A 452 SHEET 4 G 5 GLU A 492 THR A 497 1 O VAL A 496 N PHE A 440 SHEET 5 G 5 LYS A 530 TRP A 535 1 O ALA A 534 N THR A 497 SHEET 1 H 3 ILE B 47 LYS B 49 0 SHEET 2 H 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 H 3 PHE B 130 ILE B 132 -1 N ILE B 132 O ILE B 142 SHEET 1 I 2 VAL B 60 ILE B 63 0 SHEET 2 I 2 ARG B 72 VAL B 75 -1 O ARG B 72 N ILE B 63 SHEET 1 J 3 SER B 105 ASP B 110 0 SHEET 2 J 3 ASP B 186 SER B 191 -1 O VAL B 189 N THR B 107 SHEET 3 J 3 VAL B 179 TYR B 183 -1 N VAL B 179 O GLY B 190 SHEET 1 K 2 TRP B 252 THR B 253 0 SHEET 2 K 2 VAL B 292 ILE B 293 -1 O ILE B 293 N TRP B 252 SHEET 1 L 5 LYS B 347 ALA B 355 0 SHEET 2 L 5 GLN B 336 GLU B 344 -1 N ILE B 341 O LYS B 350 SHEET 3 L 5 ILE B 326 GLY B 333 -1 N ILE B 326 O TYR B 342 SHEET 4 L 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 L 5 GLU B 413 PHE B 416 1 O GLU B 415 N LEU B 391 LINK C LEU A 279 N CSD A 280 1555 1555 1.33 LINK C CSD A 280 N LYS A 281 1555 1555 1.33 CISPEP 1 PRO A 225 PRO A 226 0 -0.30 CISPEP 2 PRO A 420 PRO A 421 0 -0.25 SITE 1 AC1 11 LEU A 100 LYS A 101 LYS A 103 VAL A 179 SITE 2 AC1 11 TYR A 181 TYR A 188 TRP A 229 LEU A 234 SITE 3 AC1 11 HIS A 235 TYR A 318 GLU B 138 CRYST1 138.200 109.700 72.800 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007236 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009116 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013736 0.00000